Literature DB >> 17174437

Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk.

Jin Hee Kim1, Heon Kim, Kye Young Lee, Jong-Won Kang, Kwan-Hee Lee, So-Yeon Park, Ho-Il Yoon, Sang Hoon Jheon, Sook Whan Sung, Yun-Chul Hong.   

Abstract

To evaluate the role of genetic polymorphisms of AhR related to the carcinogen metabolism and cell proliferation, genotypes of three AhR polymorphisms Ex1+185A>G, IVS7+33T>G and Ex10+501G>A were determined in 616 lung cancer cases and 616 lung cancer-free controls. When the effect of each AhR allele on lung cancer risk was evaluated, any AhR genotype did not show the association with lung cancer risk. However, when haplotypes were composed of three AhR SNP sites, non-smokers with GGG haplotype (adjusted OR=1.7, 95% CI, 1.06-2.71) and smokers without GGG haplotype (adjusted OR=2.5, 95% CI, 1.64-3.74) showed significantly increased risk of lung cancer compared to non-smokers without GGG haplotype. Moreover, smokers with GGG haplotype showed the highest risk (adjusted OR=3.2, 95% CI, 2.10-4.74). Particularly, the synergistic effect between AhR haplotype and smoking was more apparent in squamous cell carcinoma (adjusted OR=6.1, 95% CI, 2.53-14.68). This result suggests that haplotypes of AhR gene play an important role in the development of lung cancer and there is a synergistic interaction between AhR gene and smoking for lung cancer risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174437     DOI: 10.1016/j.lungcan.2006.11.010

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

1.  The aryl hydrocarbon receptor contributes to the proliferation of human medulloblastoma cells.

Authors:  Daniel P Dever; Lisa A Opanashuk
Journal:  Mol Pharmacol       Date:  2012-02-06       Impact factor: 4.436

Review 2.  How cigarette smoke skews immune responses to promote infection, lung disease and cancer.

Authors:  Martin R Stämpfli; Gary P Anderson
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

3.  International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants.

Authors:  Therese Truong; Wiebke Sauter; James D McKay; H Dean Hosgood; Carla Gallagher; Christopher I Amos; Margaret Spitz; Joshua Muscat; Philip Lazarus; Thomas Illig; H Erich Wichmann; Heike Bickeböller; Angela Risch; Hendrik Dienemann; Zuo-Feng Zhang; Behnaz Pezeshki Naeim; Ping Yang; Shanbeh Zienolddiny; Aage Haugen; Loïc Le Marchand; Yun-Chul Hong; Jin Hee Kim; Eric J Duell; Angeline S Andrew; Chikako Kiyohara; Hongbing Shen; Keitaro Matsuo; Takeshi Suzuki; Adeline Seow; Daniel P K Ng; Qing Lan; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Vali Constantinescu; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Neil E Caporaso; Demetrius Albanes; Michael Thun; Maria Teresa Landi; Joanna Trubicka; Marcin Lener; Jan Lubinski; Ying Wang; Amélie Chabrier; Paolo Boffetta; Paul Brennan; Rayjean J Hung
Journal:  Carcinogenesis       Date:  2010-01-27       Impact factor: 4.944

4.  Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO).

Authors:  Claire H Kim; Yuan-Chin Amy Lee; Rayjean J Hung; Sheila R McNallan; Michele L Cote; Wei-Yen Lim; Shen-Chih Chang; Jin Hee Kim; Donatella Ugolini; Ying Chen; Triantafillos Liloglou; Angeline S Andrew; Tracy Onega; Eric J Duell; John K Field; Philip Lazarus; Loic Le Marchand; Monica Neri; Paolo Vineis; Chikako Kiyohara; Yun-Chul Hong; Hal Morgenstern; Keitaro Matsuo; Kazuo Tajima; David C Christiani; John R McLaughlin; Vladimir Bencko; Ivana Holcatova; Paolo Boffetta; Paul Brennan; Eleonora Fabianova; Lenka Foretova; Vladimir Janout; Jolanta Lissowska; Dana Mates; Peter Rudnai; Neonila Szeszenia-Dabrowska; Anush Mukeria; David Zaridze; Adeline Seow; Ann G Schwartz; Ping Yang; Zuo-Feng Zhang
Journal:  Int J Cancer       Date:  2014-03-25       Impact factor: 7.396

5.  Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart.

Authors:  Maria Volkova; Monica Palmeri; Kerry S Russell; Raymond R Russell
Journal:  Cardiovasc Res       Date:  2011-01-13       Impact factor: 10.787

6.  An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells.

Authors:  Kai Wang; Yan Li; Yi-Zhou Jiang; Cai-Feng Dai; Manish S Patankar; Jia-Sheng Song; Jing Zheng
Journal:  Cancer Lett       Date:  2013-07-09       Impact factor: 8.679

7.  Analysis of the AHR gene proximal promoter GGGGC-repeat polymorphism in lung, breast, and colon cancer.

Authors:  Barbara C Spink; Michael S Bloom; Susan Wu; Stewart Sell; Erasmus Schneider; Xinxin Ding; David C Spink
Journal:  Toxicol Appl Pharmacol       Date:  2014-11-04       Impact factor: 4.219

8.  Treatment of mice with the Ah receptor agonist and human carcinogen dioxin results in altered numbers and function of hematopoietic stem cells.

Authors:  Kameshwar P Singh; Amber Wyman; Fanny L Casado; Russell W Garrett; Thomas A Gasiewicz
Journal:  Carcinogenesis       Date:  2008-09-26       Impact factor: 4.944

9.  The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappaB family member RelB.

Authors:  Carolyn J Baglole; Sanjay B Maggirwar; Thomas A Gasiewicz; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

10.  Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus.

Authors:  Kimberly L Mahler; Jessica L Fleming; Amy M Dworkin; Nicholas Gladman; Hee-Yeon Cho; Jian-Hua Mao; Allan Balmain; Amanda Ewart Toland
Journal:  BMC Genomics       Date:  2008-12-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.